Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2022-01-10 Capital/Financing Update
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement involving a convertible promissory note and securities purchase agreement. It details the terms of the financing transaction, including conversion rights, interest, maturity, and default events. There are no financial statements or comprehensive financial data presented, only a description of a financing event. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is sufficient and contains detailed terms of the financing, confirming it is not a mere announcement or certification but a substantive filing about a capital transaction.
2022-01-10 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a securities purchase agreement involving a convertible promissory note, detailing terms of the note, conversion rights, interest rates, and events of default. It also references exhibits containing the full agreements. The document is not a full financial report but rather an announcement of a financing transaction and related agreements. It fits the category of Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length (7861 characters) and detailed description support this classification with high confidence.
2021-12-13 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 30, 2021, by Propanc Biopharma, Inc. It reports the entry into a material definitive agreement, specifically a Common Stock Purchase Agreement with Dutchess Capital Growth Fund LP for an equity financing facility. The document details the terms of the agreement, including the commitment amount, conditions for draw downs, and registration rights. It also includes unregistered sales of equity securities and references exhibits containing the full agreements. The Form 8-K is a current report used to announce significant events or agreements, particularly related to capital raising or financing activities. This fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing agreement, not just an announcement or summary, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2021-12-07 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It details the entry into a material definitive agreement involving a convertible promissory note and securities purchase agreement. The content focuses on financing activities, including terms of the note, conversion rights, events of default, and related agreements. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The primary subject is a capital raising transaction and related financing terms. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2021-12-01 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2021-11-12 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a securities purchase agreement and issuance of a convertible promissory note, detailing terms of the financing transaction, including conversion rights, interest, maturity, and default events. It does not contain financial statements or comprehensive financial performance data but focuses on a capital raising event and related agreements. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories. The document length is over 11,000 characters and contains detailed transaction information, not just an announcement or certification, so it is not RPA or RNS. Therefore, the appropriate classification is CAP with high confidence.
2021-10-27 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.